CLINICAL TRIALS PROFILE FOR LEDIPASVIR; SOFOSBUVIR

All Clinical Trials for LEDIPASVIR; SOFOSBUVIR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01473472 ↗	On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men	Completed	ANRS, Emerging Infectious Diseases	Phase 3	2012-01-01	This phase III, multi-centre, comparative, double-blind, randomized trial on 2 parallel groups is designed to evaluate a strategy for the prevention of HIV infection including "on demand" antiretroviral pre-exposure with Truvada versus placebo, associated with overall prevention (counselling, condoms, sexually transmitted diseases (STD) screening, hepatitis B virus (HBV) and hepatitis A virus (HAV) vaccinations and post-exposure treatment of HIV infection) in men who have sex with men (MSM), exposed to the risk of HIV infection. Indeed recent studies have reported a higher incidence of new HIV infection in MSM as compared to the general population, new approaches to the prevention of HIV infection are, therefore, necessary in order to consider the limits of current strategies.
NCT01473472 ↗	On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men	Completed	French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)	Phase 3	2012-01-01	This phase III, multi-centre, comparative, double-blind, randomized trial on 2 parallel groups is designed to evaluate a strategy for the prevention of HIV infection including "on demand" antiretroviral pre-exposure with Truvada versus placebo, associated with overall prevention (counselling, condoms, sexually transmitted diseases (STD) screening, hepatitis B virus (HBV) and hepatitis A virus (HAV) vaccinations and post-exposure treatment of HIV infection) in men who have sex with men (MSM), exposed to the risk of HIV infection. Indeed recent studies have reported a higher incidence of new HIV infection in MSM as compared to the general population, new approaches to the prevention of HIV infection are, therefore, necessary in order to consider the limits of current strategies.
NCT01701401 ↗	Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV	Completed	Gilead Sciences	Phase 3	2012-09-01	The purpose of this study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir (LDV)/sofosbuvir (SOF) fixed-dose combination (FDC) tablets with or without ribavirin (RBV) administered for 12 and 24 weeks in treatment-naive subjects with chronic genotype 1 HCV infection.
NCT01726517 ↗	Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects	Completed	Gilead Sciences	Phase 2	2012-10-01	This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV), administered for 8 or 12 weeks of treatment in participants with chronic genotype 1 hepatitis C virus (HCV) infection who are treatment-naive, and for 12 weeks in participants who had previously received a regimen containing a protease inhibitor for the treatment of HCV.
NCT01768286 ↗	Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection	Completed	Gilead Sciences	Phase 3	2013-01-01	This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir fixed dose combination (FDC) with or without ribavirin (RBV) administered for 12 or 24 weeks in treatment-experienced subjects with chronic genotype 1 hepatitis C virus (HCV) infection.
NCT01851330 ↗	Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)	Completed	Gilead Sciences	Phase 3	2013-05-01	This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV) administered for 8 or 12 weeks in treatment-naive participants with chronic genotype 1 HCV infection.
NCT01924949 ↗	Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection	Completed	Gilead Sciences	Phase 2	2013-07-01	This study is to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with nosocomial genotype 1 hepatitis C virus (HCV) infection.

Clinical Trial Conditions for LEDIPASVIR; SOFOSBUVIR

Condition Name

Condition Name for LEDIPASVIR; SOFOSBUVIR
Intervention	Trials
Hepatitis C	22
Hepatitis C Virus Infection	14
Hepatitis C, Chronic	9
Chronic Hepatitis C	8

Condition MeSH

Condition MeSH for LEDIPASVIR; SOFOSBUVIR
Intervention	Trials
Hepatitis C	87
Hepatitis	62
Hepatitis A	41
Hepatitis C, Chronic	30

Clinical Trial Locations for LEDIPASVIR; SOFOSBUVIR

Trials by Country

Trials by Country for LEDIPASVIR; SOFOSBUVIR
Location	Trials
United States	291
Canada	22
Egypt	19
Japan	14
Italy	11

Trials by US State

Trials by US State for LEDIPASVIR; SOFOSBUVIR
Location	Trials
Texas	21
New York	20
California	20
Pennsylvania	14
North Carolina	14

Clinical Trial Progress for LEDIPASVIR; SOFOSBUVIR

Clinical Trial Phase

Clinical Trial Phase for LEDIPASVIR; SOFOSBUVIR
Clinical Trial Phase	Trials
Phase 4	22
Phase 3	24
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for LEDIPASVIR; SOFOSBUVIR
Clinical Trial Phase	Trials
Completed	65
Unknown status	16
Recruiting	7

Clinical Trial Sponsors for LEDIPASVIR; SOFOSBUVIR

Sponsor Name

Sponsor Name for LEDIPASVIR; SOFOSBUVIR
Sponsor	Trials
Gilead Sciences	46
Cairo University	3
Assiut University	3

Sponsor Type

Sponsor Type for LEDIPASVIR; SOFOSBUVIR
Sponsor	Trials
Other	113
Industry	53
NIH	4

Clinical Trials Update, Market Analysis, and Projection for Ledipasvir; Sofosbuvir

Last updated: October 28, 2025

---

Introduction

Ledipasvir and Sofosbuvir (marketed as Harvoni) represent a transformative combination therapy for hepatitis C virus (HCV) infection. Since its FDA approval in 2014, this direct-acting antiviral (DAA) regimen has significantly altered treatment landscapes, promising high cure rates with shorter, better-tolerated courses. As the global market for hepatitis C therapies evolves, understanding recent clinical developments, market dynamics, and future projections is vital for industry stakeholders, healthcare providers, and investors.

---

Clinical Trials Update

Regulatory Milestones and Recent Trials

Ledipasvir/Sofosbuvir (LDV/SOF) has undergone extensive clinical testing across various HCV genotypes, patient populations, and treatment paradigms. The landmark ION program—comprising multiple phase III trials—established its efficacy and safety, leading to regulatory approval [1].

Post-approval, ongoing studies aim to optimize treatment regimens, address resistant viral strains, and expand indications to special populations. Notably, the ION-4 trial assessed LDV/SOF in HCV/HIV co-infected patients, demonstrating sustained virologic response (SVR) rates exceeding 95%. The EURIST trial evaluated shortened courses in specific patient subsets, exploring 8-week regimens with promising outcomes [2].

Real-World Evidence

Recent observational studies reinforce clinical trial findings, confirming high SVR rates (>95%) in diverse settings. Data from registries in Europe and North America highlight the regimen's robustness across age groups and comorbidities, including cirrhotic and previously treatment-experienced patients [3].

Emerging Research and Future Trials

Current investigations are focusing on relapse prevention, drug-drug interactions, and pediatric applications. Trials such as those assessing LDV/SOF in adolescents signal impending label expansions. Additionally, research into resistance-associated substitutions (RASs) continues, guiding personalized therapy decisions [4].

---

Market Analysis

Market Size and Growth Drivers

The global hepatitis C market was valued at approximately USD 18 billion in 2022, with projections to reach USD 25 billion by 2027, growing at a CAGR of 6-7% [5]. Ledipasvir/Sofosbuvir commands a significant share owing to its efficacy, safety profile, and once-daily oral dosing.

The key drivers include:

• Increased diagnosis and screening: WHO estimates over 70 million HCV infections worldwide, with many undiagnosed, creating a substantial treatment gap [6].
• Treatment accessibility: Generic formulations and pricing strategies have improved affordability, especially in low- and middle-income countries.
• Policy and guideline updates: Inclusion of LDV/SOF in standard treatment protocols has driven uptake in both public and private sectors.

Market Penetration and Competition

Initially, LDV/SOF dominated the market, but newer combinations like Vosevi (Sofosbuvir/Velpatasvir), Mavyret (Glecaprevir/Pibrentasvir), and Epclusa (Sofosbuvir/Velpatasvir) intensified competition. Despite this, LDV/SOF's high cure rates and proven safety continue to sustain its popularity, especially where resistance profiles favor ledipasvir-based regimens.

Geographically, North America and Europe constitute the largest markets, driven by high diagnosis rates and healthcare infrastructure. Emerging markets, including India, Egypt, and Southeast Asia, show rapid growth due to government initiatives and generic availability.

Pricing and Reimbursement Landscape

Pricing varies globally. In the U.S., initial treatment costs ranged from USD 94,500 for a 12-week course, but discounts, patient assistance programs, and biosimilars have reduced expenses. In resource-limited settings, generic versions cost as little as USD 300 per course [7].

Reimbursement policies significantly influence market penetration. While approved in over 180 countries, access in developing nations remains constrained by high drug prices and infrastructural barriers.

---

Market Projection

Future Outlook

The hepatitis C treatment market is expected to grow steadily, driven by:

• Continued diagnosis efforts: WHO’s goal to eliminate HCV as a public health threat by 2030 hinges on expanding screening and treatment.
• Regulatory expansions: Ongoing trials in pediatric populations and genotype-specific indications will broaden LDV/SOF's market.
• Combination therapies and simplified regimens: The trend toward pan-genotypic, ribavirin-free regimens aims to replace genotype-specific therapies, but LDV/SOF retains a prominent niche.

Revenue Forecasts

By 2030, the market for Ledipasvir/Sofosbuvir is projected to stabilize or decline slightly as newer regimens gain market share, but revenues will remain robust due to existing patient pools. Estimated global sales could range from USD 15-20 billion annually by 2027, with North America leading the demand.

Factors Influencing Market Dynamics

• Generic drug entry: Will continue to decrease prices and expand access, especially in developing markets.
• Public health initiatives: Greater screening and treatment campaigns will sustain demand.
• Resistance concerns: Monitor RASs; if resistance development becomes prominent, product demand could be impacted.
• Brand loyalty and clinician preference: Based on efficacy, safety, and patient adherence factors.

---

Conclusion

Ledipasvir/Sofosbuvir remains a cornerstone of hepatitis C therapy, supported by robust clinical data and significant market presence. Ongoing clinical trials bolster its versatility and therapeutic scope, while market dynamics are influenced by generics, policy shifts, and global health initiatives. The drug's future will depend on patient access, development of real-world evidence, and integration into comprehensive hepatitis C elimination strategies.

---

Key Takeaways

• Clinical Success: Multiple phase III trials confirm LDV/SOF's high SVR rates (>95%) across diverse patient populations, including co-infected and cirrhotic patients.
• Market Position: Despite increasing competition, LDV/SOF maintains a dominant position due to proven efficacy, safety, and global familiarity.
• Global Access: Generic formulations and strategic pricing in emerging markets will expand access, supporting public health efforts.
• Future Growth: The hepatitis C market will grow steadily, supported by enhanced screening, policy support, and expanded indications, although newer pan-genotypic drugs may influence long-term sales.
• Challenges: Resistance development, reimbursement hurdles, and drug pricing remain critical factors impacting market penetration and sustainability.

---

FAQs

1. What are the latest clinical trial developments for Ledipasvir/Sofosbuvir?
Recent studies focus on optimizing treatment duration, expanding age groups to pediatric populations, and assessing efficacy in special populations. Trials like ION-4 continue to demonstrate high SVR rates in HCV/HIV co-infected patients, reinforcing the regimen's versatility.

2. How does the market for Ledipasvir/Sofosbuvir compare to competitors?
While newer pan-genotypic regimens have emerged, LDV/SOF's established efficacy and safety profile maintain substantial market share. Its focus on specific genotypes and proven track record keep it relevant, especially in regions with existing infrastructure.

3. What factors are driving the growth of hepatitis C treatments globally?
Key factors include improved detection through screening campaigns, reduced drug costs via generics, supportive policy initiatives, and increasing awareness of hepatitis C's health burden.

4. Will the market for Ledipasvir/Sofosbuvir decline with the advent of newer regimens?
Potentially, but current data suggests it will remain relevant through the 2020s, especially in emerging markets and for patients contraindicated for newer therapies. The high efficacy in existing patient pools sustains demand.

5. What are the primary hurdles to expanding access to Ledipasvir/Sofosbuvir?
Pricing and reimbursement challenges, especially in low-income settings, coupled with infrastructural barriers for screening and diagnosis, hinder widespread access. Continued negotiations and public health initiatives aim to address these issues.

---

Sources

[1] Gilead Sciences. (2014). FDA approves Harvoni for treatment of most hepatitis C genotypes.
[2] Feld, J.J. et al. (2015). Ledipasvir and Sofosbuvir for 8 Weeks to Treat Early Hepatitis C Virus: The ION-3 Trial. New England Journal of Medicine.
[3] World Health Organization. (2022). Global hepatitis report 2022.
[4] Lenz, O. et al. (2016). Resistance-associated substitutions in chronic hepatitis C: implications for therapy. J Hepatol.
[5] Mordor Intelligence. (2022). Hepatitis C Therapeutics Market - Growth, Trends, and Forecasts.
[6] WHO. (2017). Global hepatitis report.
[7] Dore, G.J., & Thorpe, H. (2018). The pricing of Hepatitis C drugs and access in developing countries. Lancet Global Health.